Citius Oncology, Inc. Other Expenses
Citius Oncology, Inc. (CTOR) reported Other Expenses of $27.94 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherExpenses · last filed 2026-08-14
- Citius Oncology, Inc. other expenses for the quarter ending 2026-06-30 was $27.94K, a 0.00% change year-over-year.
- Citius Oncology, Inc. other expenses for the quarter ending 2026-03-31 was $27.94K, a 8.00% decline year-over-year.
- Citius Oncology, Inc. other expenses for the quarter ending 2025-12-31 was $27.94K, a 8.00% decline year-over-year.
- Citius Oncology, Inc. other expenses for the quarter ending 2025-09-30 was $27.94K, a 8.30% decline year-over-year.
- Citius Oncology, Inc. other expenses for fiscal 2025 was $114.19K, a 6.07% decline from fiscal 2024.
- Citius Oncology, Inc. other expenses for fiscal 2024 was $121.57K, a 0.08% increase from fiscal 2023.
- Citius Oncology, Inc. other expenses for fiscal 2023 was $121.47K.
| Period end | Other Expenses 3 month | Other Expenses 6 month | Other Expenses 9 month | Other Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.94K 10-Q · filed 2026-08-14 | $55.88K derived: sum of 2 quarters · filed 2026-08-14 | $83.82K 10-Q · filed 2026-08-14 | $111.76K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $27.94K 10-Q · filed 2026-05-15 | $55.88K 10-Q · filed 2026-05-15 | $83.82K derived: sum of 3 quarters · filed 2026-05-15 | $111.76K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $27.94K 10-Q · filed 2026-02-13 | $55.88K derived: sum of 2 quarters · filed 2026-02-13 | $83.82K derived: sum of 3 quarters · filed 2026-08-14 | $114.19K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $27.94K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $55.88K derived: sum of 2 quarters · filed 2026-08-14 | $86.25K derived: sum of 3 quarters · filed 2026-08-14 | $114.19K 10-K · filed 2025-12-23 |
| 2025-06-30 | $27.94K 10-Q · filed 2026-08-14 | $58.31K derived: sum of 2 quarters · filed 2026-08-14 | $86.25K 10-Q · filed 2026-08-14 | $119.14K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $30.37K 10-Q · filed 2026-05-15 | $58.31K 10-Q · filed 2026-05-15 | $91.20K derived: sum of 3 quarters · filed 2026-05-15 | $121.57K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $30.37K 10-Q · filed 2026-02-13 | $60.84K derived: sum of 2 quarters · filed 2026-02-13 | $91.20K derived: sum of 3 quarters · filed 2026-02-13 | $119.14K derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $30.47K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $60.84K derived: sum of 2 quarters · filed 2025-12-23 | $88.77K derived: sum of 3 quarters · filed 2025-12-23 | $121.57K 10-K · filed 2025-12-23 |
| 2024-06-30 | $30.37K 10-Q · filed 2025-08-12 | $58.31K derived: sum of 2 quarters · filed 2025-08-12 | $91.10K 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $27.94K 10-Q · filed 2025-05-14 | $60.73K 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $30.37K 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | $121.47K 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |